These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

434 related articles for article (PubMed ID: 28216072)

  • 61. Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus.
    Stohl W; Hiepe F; Latinis KM; Thomas M; Scheinberg MA; Clarke A; Aranow C; Wellborne FR; Abud-Mendoza C; Hough DR; Pineda L; Migone TS; Zhong ZJ; Freimuth WW; Chatham WW; ;
    Arthritis Rheum; 2012 Jul; 64(7):2328-37. PubMed ID: 22275291
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Efficacy, pharmacokinetic and pharmacodynamic profile of belimumab for systemic lupus erythematosus.
    Jordan NP; D'Cruz DP
    Expert Opin Drug Metab Toxicol; 2015; 11(10):1635-45. PubMed ID: 26327145
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Clinical efficacy of belimumab in central nervous system demyelinating syndromes with systemic lupus erythematosus: A case series.
    Liu Y; Fan Q; Jia C; Wan Q; Yang H
    Medicine (Baltimore); 2023 Jun; 102(25):e34079. PubMed ID: 37352070
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Performance of SLE responder index and lupus low disease activity state in real life: A prospective cohort study.
    Ramirez GA; Canti V; Moiola L; Magnoni M; Rovere-Querini P; Coletto LA; Dagna L; Manfredi AA; Bozzolo EP
    Int J Rheum Dis; 2019 Sep; 22(9):1752-1761. PubMed ID: 31379114
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Efficacy of belimumab in two serologically distinct high disease activity subgroups of patients with systemic lupus erythematosus: post-hoc analysis of data from the phase III programme.
    Maslen T; Bruce IN; D'Cruz D; Ianosev M; Bass DL; Wilkinson C; Roth DA
    Lupus Sci Med; 2021 Feb; 8(1):. PubMed ID: 33568389
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials.
    Strand V; Levy RA; Cervera R; Petri MA; Birch H; Freimuth WW; Zhong ZJ; Clarke AE;
    Ann Rheum Dis; 2014 May; 73(5):838-44. PubMed ID: 23524886
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Belimumab restores Treg/Th17 balance in patients with refractory systemic lupus erythematosus.
    Prete M; Leone P; Frassanito MA; Desantis V; Marasco C; Cicco S; Dammacco F; Vacca A; Racanelli V
    Lupus; 2018 Oct; 27(12):1926-1935. PubMed ID: 30180771
    [TBL] [Abstract][Full Text] [Related]  

  • 68. A 6-month open-label extension study of the safety and efficacy of subcutaneous belimumab in patients with systemic lupus erythematosus.
    Doria A; Bass D; Schwarting A; Hammer A; Gordon D; Scheinberg M; Fox NL; Groark J; Stohl W; Kleoudis C; Roth D
    Lupus; 2018 Aug; 27(9):1489-1498. PubMed ID: 29807477
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Efficacy and safety of biologic therapies for systemic lupus erythematosus treatment: systematic review and meta-analysis.
    Borba HH; Wiens A; de Souza TT; Correr CJ; Pontarolo R
    BioDrugs; 2014 Apr; 28(2):211-28. PubMed ID: 24190520
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus.
    Furie R; Stohl W; Ginzler EM; Becker M; Mishra N; Chatham W; Merrill JT; Weinstein A; McCune WJ; Zhong J; Cai W; Freimuth W;
    Arthritis Res Ther; 2008; 10(5):R109. PubMed ID: 18786258
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus Erythematosus.
    Wallace DJ; Ginzler EM; Merrill JT; Furie RA; Stohl W; Chatham WW; Weinstein A; McKay JD; McCune WJ; Petri M; Fettiplace J; Roth DA; Ji B; Heath A
    Arthritis Rheumatol; 2019 Jul; 71(7):1125-1134. PubMed ID: 30771238
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The use of belimumab on patients with both systemic lupus erythematosus and immune thrombocytopenia: A retrospective cohort study.
    Wu Q; Zhao MX; Huang XS; Lin CS; Xu Q
    Lupus; 2024 May; 33(6):608-614. PubMed ID: 38518059
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Association of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index with measures of disease activity and health status in patients with systemic lupus erythematosus.
    Stoll T; Stucki G; Malik J; Pyke S; Isenberg DA
    J Rheumatol; 1997 Feb; 24(2):309-13. PubMed ID: 9034988
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Effectiveness and safety of belimumab in patients with systemic lupus erythematosus in a real-world setting.
    Anjo C; Mascaró JM; Espinosa G; Cervera R
    Scand J Rheumatol; 2019 Nov; 48(6):469-473. PubMed ID: 31264525
    [No Abstract]   [Full Text] [Related]  

  • 75. Autoantibody and Cytokine Profiles during Treatment with Belimumab in Patients with Systemic Lupus Erythematosus.
    Parodis I; Åkerström E; Sjöwall C; Sohrabian A; Jönsen A; Gomez A; Frodlund M; Zickert A; Bengtsson AA; Rönnelid J; Gunnarsson I
    Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32422945
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Belimumab: anti-BLyS human monoclonal antibody, anti-BLyS monoclonal antibody, BmAb, human monoclonal antibody to B-lymphocyte stimulator.
    Drugs R D; 2008; 9(3):197-202. PubMed ID: 18457473
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Effect of Disease Activity on Organ Damage Progression in Systemic Lupus Erythematosus: University of Toronto Lupus Clinic Cohort.
    Urowitz MB; Gladman DD; Ibañez D; Su J; Mursleen S; Sayani A; Ross Terres JA; Iczkovitz S
    J Rheumatol; 2021 Jan; 48(1):67-73. PubMed ID: 32238510
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Impact of systemic lupus erythematosus disease activity, hydroxychloroquine and NSAID on the risk of subsequent organ system damage and death: analysis in a single US medical centre.
    Hill DD; Eudy AM; Egger PJ; Fu Q; Petri MA
    Lupus Sci Med; 2021 Apr; 8(1):. PubMed ID: 33832976
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Application of SLE-DAS to assess subcutaneous belimumab efficacy in a cohort of systemic lupus erythematosus patients.
    Ceccarelli F; Picciariello L; Natalucci F; Moretti V; Spinelli FR; Alessandri C; Conti F
    Clin Exp Rheumatol; 2024 Jul; 42(7):1491-1494. PubMed ID: 38819948
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Breaking the ice in systemic lupus erythematosus: belimumab, a promising new therapy.
    Mosak J; Furie R
    Lupus; 2013 Apr; 22(4):361-71. PubMed ID: 23553779
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.